Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

The Efficacy and Safety of Pharmacoinvasive Therapy With Prourokinase for Acute ST Segment Elevation Myocardial Infarction Patients With Expected Percutaneous Coronary Intervention Related Delay

NCT01642667 is registered in ClinicalTrials.gov with Suzhou Landing Pharmaceuticals as lead sponsor.

NCT NCT01642667
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01642667 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
The Efficacy and Safety of Pharmacoinvasive Therapy With Prourokinase for Acute ST Segment Elevation Myocardial Infarction Patients With Expected Percutaneous Coronary Intervention Related Delay
Lead sponsor
Suzhou Landing Pharmaceuticals
Phase
Phase 2/3
Overall status
Completed
Start date
November 30, 2008
Completion date
December 31, 2010
Enrollment
197 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

st-segment elevation myocardial infarction (stemi)